
News
Home>News & Events>Publications>TTC>On September 25th, the FDA published a Personal Viewpoint in the American Journal of Transplantation
357
Related Posts
-
Longitudinal estimated glomerular filtration rate (eGFR) modeling in long-term renal function to inform clinical trial design in kidney transplantation
-
Acute Rejection After Kidney Transplant—An Endpoint Not Predictive of Treatment Effect on Graft Survival
-
The Role of Patient-reported Outcomes and Medication Adherence Assessment in Patient-focused Drug Development for Solid Organ Transplantation
-
Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: the 2019 Expert Consensus From the Transplant Society Working Group
-
Use of Biomarkers to Improve Immunosuppressive Drug Development and Outcomes in Renal Organ Transplantation: A Meeting Report